Posted by Michael Wonder on 21 Nov 2025
Alnylam's ATTR cardiomyopathy drug backed for NHS use
21 November 2025 - Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra.
The ruling by reimbursement authority NICE means that Amvuttra (vutrisiran) can be used to treat wild-type or hereditary ATTR amyloidosis with cardiomyopathy in adults, two years after it was cleared for use by the NHS to treat polyneuropathy associated with the disorder.
